期刊
PHARMACEUTICALS
卷 15, 期 3, 页码 -出版社
MDPI
DOI: 10.3390/ph15030354
关键词
West Nile virus; Zika virus; MVA; vaccine; cross-protection; immunogenicity; antibody-dependent enhancement of infection; vaccine safety
资金
- Ministerio de Ciencia e Innovacion, Agencia Estatal de Investigacion MCIN/AEI [PID2020-11919JRJ-100, PID2019-105117RR-C21, E-RTA-2017-00003-C03]
- Comunidad de Madrid [P2018/BAA-4370 PLATESA2-CM]
- Ministerio de Economia y Competitividad (AEI/MINECO/FEDER-EU) [SAF2013-45232-R, SAF2017-88089-R]
- Spanish Ministry of Health and Education of Spain
The Zika virus is a flavivirus transmitted by mosquitoes, which can cause birth defects and Guillain-Barre syndrome. Recent local infections in Europe and the spread of the Asian tiger mosquito raise concerns about future outbreaks in this region. However, the antigenic similarities of Zika with other flaviviruses pose challenges for vaccine development. This study found low cross-reactivity and no antibody-dependent enhancement between the Zika vaccine candidate and the West Nile virus, supporting the safety of the vaccine in areas where West Nile virus is endemic.
Zika virus (ZIKV) is a mosquito-borne flavivirus whose infection in pregnant women is associated with a spectrum of birth defects, which are together referred as Congenital Zika Syndrome. In addition, ZIKV can also induce Guillain-Barre syndrome, which is an autoimmune disease with neurological symptoms. The recent description of the first local infections of ZIKV in the European continent together with the expansion of one of its potential vectors, the Asian tiger mosquito (Aedes albopictus), invite us to be prepared for future outbreaks of ZIKV in this geographical region. However, the antigenic similarities of ZIKV with other flaviviruses can lead to an immune cross-reactivity with other circulating flaviviruses inducing, in some cases, flavivirus-disease exacerbation by antibody-dependent enhancement (ADE) of infection, which is a major concern for ZIKV vaccine development. Until now, West Nile virus (WNV) is the main medically relevant flavivirus circulating in the Mediterranean Basin. Therefore, anticipating the potential scenario of emergency vaccination against ZIKV in areas of Europe where WNV is endemic, in this investigation, we have evaluated the cross-reactivity between WNV and our previously developed ZIKV vaccine candidate based on modified vaccinia virus Ankara (MVA) vector expressing ZIKV structural proteins (MVA-ZIKV). To this end, mice were first immunized with MVA-ZIKV, subsequently challenged with WNV, and then, the ZIKV- and WNV-specific immune responses and protection against WNV were evaluated. Our results indicate low cross-reactivity between the MVA-ZIKV vaccine candidate and WNV and absence of ADE, supporting the safety of this ZIKV vaccine candidate in areas where the circulation of WNV is endemic.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据